Ongoing
A randomized controlled, open-label trial examining the efficacy, safety, and tolerability of ablative therapies for high-grade anal dysplasia versus observation alone in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreOngoing
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreCompleted
Evaluation of E/C/F/TAF switch followed by ledipasivir-sofosbuvir antiviral HCV therapy in HIV-HCV co-infection
Learn MoreReporting
Optimizing the delivery of HIV post-exposure prophylaxis: A randomized controlled trial of text messaging support and physician to nurse task-shifting
Learn MoreReporting
Completed
Valacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
Learn MoreOngoing
A study of an HPV VLP vaccine in a cohort of HIV positive girls and women
Learn MoreCompleted
A Phase II, prospective, open-label, pilot study of the tolerability, safety, and efficacy of Argon plasma coagulation for the treatment of anal intraepithelial neoplasia grade 2 or 3 in HIV-positive men having sex with men
Learn MoreCompleted
Evaluation of SQ32,756 (BV ara U) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV Infected Patients
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
